Posted by Michael Wonder on 09 May 2026
Lilly's Retevmo moves closer to Korea reimbursement coverage after key review approval
8 May 2026 - Retevmo (selpercatinib), a targeted therapy for RET gene mutation-driven cancers, has cleared a major hurdle toward reimbursement under Korea’s national health insurance system.
On Thursday, the Health Insurance Review and Assessment Service announced the results of the fifth Pharmaceutical Reimbursement Evaluation Committee (PREC) meeting of 2026, concluding that reimbursement for Retevmo capsules in 40 mg and 80 mg formulations was appropriate.
